The company plays a role in the crucial phase of process development and batches manufacturing for pre-clinical and clinical studies, where the human safety and efficacy of a new drug have to be confirmed. Areta can tailor the production schedule to the real need of the customer avoiding massive production at the beginning of the project ( that may result in huge losses of product and money) by the proper application of process development to built a robust process for the advanced phases in the long trail of a drug to become a product. With this aim the company has been organized in two divisions:
ARETA GMP, with a high containment plant for cell culture authorized by the Italian Ministry of Health to the GMP production of batches for Phase I and Phase II clinical studies
ARETA RESEARCH, specialized in generationand production of monoclonal antibodies and set up of immunological and cell based tests needed for characterization and quality control of new biodrugs during their development.
